YIH
CRVS icon

Y-Intercept (HK)’s Corvus Pharmaceuticals CRVS Stock Holding History

Y-Intercept (HK)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Buy
+43,769
New +$607K 0.01% 1224

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Y-Intercept (HK)'s CRVS Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 43,769 shares worth $654K. The stake represents 0.01% of the portfolio and ranks #1224 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Y-Intercept (HK) held 43,769 shares of Corvus Pharmaceuticals worth $654K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1224 holding.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.